IL2RA and Merkel cell skin cancer: Also, ipilimumab, a cytotoxic T-lymphocyte protein 4 inhibitor, targets CTLA4, and aldesleukin, an interleukin-2 receptor agonist, targets IL2RA; current clinical trials are testing therapies based on these drugs for Merkel cell skin cancer and other skin cancers48–50.